Table 4 The multivariate cox regression analysis in cervical cancer patients

The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells (n = 197)

 Clinical stage (I/II–IV)

3.827 (1.585–9.241)

0.003

4.248 (1.886–9.571)

 < 0.001

 Tumor (T) status (1/2–4)

–

–

–

–

 Nodal (N) status (0/1)

3.219 (1.197–8.653)

0.021

–

–

 METTL3 in tumor cells (low/high)

3.157 (1.181–8.438)

0.022

3.271 (1.303–8.213)

0.012

 METTL3 in tumor-infiltrating immune cells (low/high)

3.368 (1.080–10.502)

0.036

1.006(0.202–5.013)

0.994

 Number of CD33⁺ MDSCs (low/high)

3.958(1.138–13.767)

0.031

–

–

The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage II–IV (n = 70)

 Tumor (T) status (1/2–4)

–

–

0.173 (0.023–1.317)

0.090

 METTL3 in tumor cells (low/high)

6.725 (1.576–28.696)

0.010

5.140 (1.286–20.548)

0.021

 METTL3 in tumor-infiltrating immune cells (low/high)

2.053 (0.483–8.726)

0.330

2.149 (0.541–8.540)

0.277

 Number of CD33⁺ MDSCs (low/high)

–

–

8.802 (1.136–68.233)

0.037